ArticleRespiratory research2025
Modulation of NEAT1 and MALAT1 expression in WJ-MSCs by Covid-19 serum: a foundation for EVs-mediated therapy.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs)-based and MSCs-derived extracellular vesicle (EV) therapies, have garnered significant attention as potential treatments for severe Coronavirus disease 19 (Covid-19), leading to evaluation in numerous clinical trials. This interest stems from the observed ability of MSCs, and their EVs, to mitigate the hyper-inflammatory state that characterizes severe cases of the disease. However, despite the promising preclinical and early clinical results, the precise mechanisms of action remain unclear, hindering therapy optimization.
methodsThis study investigated the response of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) to a diverse panel of sera collected from multiple hospitalized Covid-19 patients, aiming to recapitulate in vitro the spectrum of inflammatory conditions MSCs encounter in vivo.
resultsExposure to Covid-19 serum activated WJ-MSCs, increasing proliferation and RNA/protein synthesis. Transcriptomic analysis revealed an early and significant downregulation of the inflammation-related long non-coding RNAs (lncRNAs) NEAT1 and MALAT1. This downregulation of NEAT1 and MALAT1, triggered by Covid-19 serum, suggests a potential mechanism by which WJ-MSCs may limit excessive inflammation. Importantly, reducing MALAT1 (and to a lesser extent NEAT1) expression in WJ-MSCs enhanced the therapeutic potential of MSC-derived EVs. This suggests that targeting pro-inflammatory lncRNAs in parental cells could be a promising therapeutic strategy for managing Covid-19 and other inflammatory lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.